This year’s Asian Pacific Lung Cancer Conference (APLCC) took place on 13-15 May at the Empress Convention Centre in Chiang Mai, Thailand. APLCC was hosted by the International Association for the Study of Lung Cancer (IASLC).
Boehringer Ingelheim hosted a satellite symposium at the congress entitled, ‘NSCLC treatment: The evolving therapeutic landscape’ which was held on Friday 13 May 2016, 17:00–18:00; The meeting was chaired by Prof. Sumitra Thongprasert, and included presentations given by Dr James Yang and Dr Nick Pavlakis.
Of special note there was a poster on the efficacy, safety and pharmacokinetics of Boehringer Ingelheim's 3rd generation irreversible EGFR mutation-selective tyrosine kinase inhibitor (BI 1482694).
An oral presentation covered the latest efficacy and safety results from the LUX-Lung 7 trial of afatinib vs gefitinib in EGFR mutation-positive patients with NSCLC (Asian population). This presentation had already been awarded best oral presentation at APLCC 2016. There was a presentation of results from the LUX-Lung 8 trial of afatinib vs erlotinib in patients with squamous cell carcinoma of the lung. This was particularly of note with the recent approval of afatinib for patients with squamous cell carcinoma of the lung in the EU and in the US.
For more details see below.
The full APLCC 2016 programme can be found here.
See the exciting Boehringer Ingelheim APLCC 2016 Satellite Symposium Agenda
17:00 – 17:05
Overview of treatment of NSCLC
17:05 – 17:30
First-line treatment of EGFR M+ NSCLC: an update on second generation tyrosine kinase inhibitors (TKIs)
17:30 – 17:40
Next-generation EGFR inhibitors: treatment options following resistance
17:40 – 17:55
Anti-angiogenic treatment in NSCLC: What we know, what we do
17:55 – 18:00
Final questions, summary and meeting close
Click here to view the invitation
Poster and oral presentations of BI 1482694 and afatinib at APLCC 2016
Poster session: Medical Oncology
Friday 13–Sunday 15
Epidermal growth factor receptor mutant-specific inhibitor BI 1482694 (HM61713) in T790M-positive non-small cell lung cancer: efficacy, safety and pharmacokinetics at the recommended Phase II dose. (Abstract No. ABS086)
Park et al.
Sequential EGFR-TKI strategy to overcome acquired resistance to afatinib: novel secondary mutations L792F and C797S in addition to T790M. (Abstract No. ABS070)
Kobayashi et al.
Afatinib versus chemotherapy for epidermal growth factor receptor mutation-positive non-small cell lung cancer patients aged ≥65 years: subgroup analyses of LUX-Lung 3 and LUX-Lung 6. (Abstract No. ABS135)
Wu et al.
Phase Ib trial of afatinib and BI 836845 in patients with advanced non-small cell lung cancer. (Abstract No. ABS150)
Tan et al.
Phase IV study of second-line afatinib in patients with locally advanced/metastatic non-small cell lung cancer harboring common epidermal growth factor receptor mutations (Del19 and/or L858R). (Abstract No. ABS157)
Thongprasert et al.
Oral presentations: Medical Oncology
Saturday 14, 16:00–17:00
First-line afatinib versus gefitinib in patients with epidermal growth factor receptor mutation positive non-small cell lung cancer (LUX-Lung 7): efficacy and safety in Asian patients. (Abstract No. ABS068)
O’Byrne et al.
Impact of dose adjustment on afatinib safety and efficacy in epidermal growth factor receptor mutation-positive non-small cell lung cancer: post-hoc analyses of LUX-Lung 3/LUX-Lung 6. (Abstract No. ABS134)
Wu et al.
Overall survival with afatinib vs chemotherapy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: LUX-Lung 3 and 6 race subgroup analyses. (Abstract No. ABS142)
Wu et al.
Phase III trial of second-line afatinib versus erlotinib in patients with squamous cell carcinoma of the lung (LUX-Lung 8): tumor genetic analysis and survival outcomes. (Abstract No. ABS168)
Park et al.